- Home
- SLM vs CRNX Comparison
SLM vs CRNX Comparison
Compare SLM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- CRNX
- Stock Information
- Founded
- SLM 1972
- CRNX 2008
- Country
- SLM United States
- CRNX United States
- Employees
- SLM N/A
- CRNX N/A
- Industry
- SLM Finance: Consumer Services
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- CRNX Health Care
- Exchange
- SLM Nasdaq
- CRNX Nasdaq
- Market Cap
- SLM 5.9B
- CRNX 5.2B
- IPO Year
- SLM N/A
- CRNX 2018
- Fundamental
- Price
- SLM $29.62
- CRNX $30.62
- Analyst Decision
- SLM Buy
- CRNX Strong Buy
- Analyst Count
- SLM 11
- CRNX 12
- Target Price
- SLM $31.18
- CRNX $73.36
- AVG Volume (30 Days)
- SLM 3.7M
- CRNX 1.1M
- Earning Date
- SLM 04-23-2025
- CRNX 05-08-2025
- Dividend Yield
- SLM 1.76%
- CRNX N/A
- EPS Growth
- SLM 11.20
- CRNX N/A
- EPS
- SLM 2.68
- CRNX N/A
- Revenue
- SLM $1,440,535,000.00
- CRNX $1,039,000.00
- Revenue This Year
- SLM $15.23
- CRNX $356.40
- Revenue Next Year
- SLM $9.04
- CRNX $845.76
- P/E Ratio
- SLM $11.05
- CRNX N/A
- Revenue Growth
- SLM N/A
- CRNX N/A
- 52 Week Low
- SLM $19.39
- CRNX $29.18
- 52 Week High
- SLM $32.65
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- SLM 50.77
- CRNX 31.91
- Support Level
- SLM $28.23
- CRNX $32.90
- Resistance Level
- SLM $30.82
- CRNX $35.26
- Average True Range (ATR)
- SLM 0.91
- CRNX 1.73
- MACD
- SLM -0.01
- CRNX -0.10
- Stochastic Oscillator
- SLM 54.02
- CRNX 19.86
About SLM SLM Corporation
SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.